Gilead Q2 2024 Earnings. Total first quarter 2024 product sales increased 5% to $6.6 billion, compared to the same period in 2023. Bagri now anticipates that the biopharmaceutical company will earn $1.40 per share for the quarter, down from their prior estimate of.
Gild stock analysts call for $26.67 billion in sales. Total product sales, excluding veklury, increased 6% to $6.1.
Us$6.69B (Up 5.3% From 1Q 2023).
Gilead now expects to earn.
Total Second Quarter 2023 Revenue Increased 5% To $6.6 Billion Compared To The Same Period In 2022, Primarily Driven By Increased Sales In Hiv And Oncology, Partially Offset By Lower Veklury® (Remdesivir) Sales.
Total product sales (including veklury):
The Biopharmaceutical Company Reported ($1.32) Earnings Per Share (Eps) For The.
Images References :
Us$6.69B (Up 5.3% From 1Q 2023).
Us$4.17b (down from us$1.01b profit in 1q 2023).
For More Than 30 Years, We’ve.
Total product sales, excluding veklury, increased 6% to $6.1.